Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L.

Cancers (Basel). 2019 Feb 21;11(2). pii: E252. doi: 10.3390/cancers11020252. Review.

2.

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Asslaber D, Wacht N, Leisch M, Qi Y, Maeding N, Hufnagl C, Jansko B, Zaborsky N, Villunger A, Hartmann TN, Greil R, Egle A.

Clin Cancer Res. 2019 Mar 15;25(6):1901-1912. doi: 10.1158/1078-0432.CCR-18-1548. Epub 2018 Nov 28.

PMID:
30487125
3.

Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.

Zaborsky N, Gassner FJ, Höpner JP, Schubert M, Hebenstreit D, Stark R, Asslaber D, Steiner M, Geisberger R, Greil R, Egle A.

Leukemia. 2019 Apr;33(4):957-968. doi: 10.1038/s41375-018-0260-4. Epub 2018 Sep 27.

PMID:
30262843
4.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Sep;97(9):1745. doi: 10.1007/s00277-018-3403-9.

PMID:
29934835
5.

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4. Erratum in: Ann Hematol. 2018 Jun 23;:.

6.

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.

Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, Hartmann TN, Greil R, Geisberger R.

Oncoimmunology. 2017 Sep 21;7(1):e1371399. doi: 10.1080/2162402X.2017.1371399. eCollection 2017.

7.

Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia.

Gassner FJ, Schubert M, Rebhandl S, Spandl K, Zaborsky N, Catakovic K, Blaimer S, Hebenstreit D, Greil R, Geisberger R.

Mol Cancer Res. 2018 Mar;16(3):428-438. doi: 10.1158/1541-7786.MCR-17-0373. Epub 2017 Dec 8.

8.

CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.

Zaborsky N, Gassner FJ, Asslaber D, Reinthaler P, Denk U, Flenady S, Hofbauer JP, Danner B, Rebhandl S, Harrer A, Geisberger R, Greil R, Egle A.

Oncotarget. 2016 Aug 2;7(31):49459-49469. doi: 10.18632/oncotarget.10372.

9.

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R.

Br J Haematol. 2015 Aug;170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4.

10.

B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

Zaborsky N, Holler C, Geisberger R, Asslaber D, Gassner FJ, Egger V, Piñón-Hofbauer J, Kocher T, Hartmann TN, Greil R, Egle A.

Haematologica. 2015 Aug;100(8):e307-10. doi: 10.3324/haematol.2015.124719. Epub 2015 Apr 24. No abstract available.

11.

AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, Hebenstreit D, Greil R, Geisberger R.

Eur J Immunol. 2014 Dec;44(12):3747-57. doi: 10.1002/eji.201344421. Epub 2014 Oct 18.

12.

Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia.

Rebhandl S, Huemer M, Zaborsky N, Gassner FJ, Catakovic K, Felder TK, Greil R, Geisberger R.

Eur J Immunol. 2014 Jul;44(7):2175-87. doi: 10.1002/eji.201343853. Epub 2014 Apr 15.

13.

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R.

Haematologica. 2014 May;99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21. No abstract available.

14.

Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.

Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Dürig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schäfer Y, Lampl B, Peschel C, Egle A, Ringshausen I.

Cancer Cell. 2013 Jan 14;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.

15.

Physicochemical characterization of recombinant allergens and hypoallergenic variants.

Himly M, Wallner M, Zaborsky N, Hauser M, Gadermaier G, Harrer A, Ferreira F.

Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess. 2013;97:101-5. No abstract available.

PMID:
24912320
16.

Response to Detection and analysis of unusual features in the structural model and structure-factor data of a birch pollen allergen.

Zaborsky N, Brunner M, Wallner M, Himly M, Karl T, Schwarzenbacher R, Ferreira F, Achatz G.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Apr 1;68(Pt 4):377. doi: 10.1107/S1744309112008433. Epub 2012 Mar 31.

17.

Lysine residue at position 22 of the AID protein regulates its class switch activity.

Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R.

PLoS One. 2012;7(2):e30667. doi: 10.1371/journal.pone.0030667. Epub 2012 Feb 20.

18.

Reshaping the Bet v 1 fold modulates T(H) polarization.

Wallner M, Hauser M, Himly M, Zaborsky N, Mutschlechner S, Harrer A, Asam C, Pichler U, van Ree R, Briza P, Thalhamer J, Bohle B, Achatz G, Ferreira F.

J Allergy Clin Immunol. 2011 Jun;127(6):1571-8.e9. doi: 10.1016/j.jaci.2011.01.064. Epub 2011 Mar 21.

19.

HAX1 deficiency: impact on lymphopoiesis and B-cell development.

Peckl-Schmid D, Wolkerstorfer S, Königsberger S, Achatz-Straussberger G, Feichtner S, Schwaiger E, Zaborsky N, Huemer M, Gratz IK, Schibli R, Lamers M, Crameri R, Moser K, Luger EO, Achatz G.

Eur J Immunol. 2010 Nov;40(11):3161-72. doi: 10.1002/eji.200940221. Epub 2010 Sep 24.

20.

HPK1 associates with SKAP-HOM to negatively regulate Rap1-mediated B-lymphocyte adhesion.

Königsberger S, Peckl-Schmid D, Zaborsky N, Patzak I, Kiefer F, Achatz G.

PLoS One. 2010 Sep 1;5(9). pii: e12468. doi: 10.1371/journal.pone.0012468.

Supplemental Content

Loading ...
Support Center